Kliovance is a continuous combined hormone replacement therapy (HRT) tablet used to manage symptoms of menopause in women who have not had a period for at least 12 months. It is prescribed to relieve common symptoms such as hot flushes, night sweats, mood swings, and vaginal dryness. Kliovance is also used to prevent osteoporosis in postmenopausal women at high risk of fractures who are unable to take other bone treatments.
How It Works
Kliovance contains two active ingredients: estradiol (a form of oestrogen) and norethisterone acetate (a synthetic progestogen). Estradiol replaces the natural oestrogen that the body no longer produces after menopause, helping to relieve symptoms caused by hormonal decline. Norethisterone counteracts the effects of oestrogen on the endometrial lining, reducing the risk of endometrial hyperplasia or cancer in women with an intact uterus. The combination offers effective symptom relief and uterine protection.
Why Choose Kliovance
Kliovance provides a low-dose, continuous combined HRT option that is well-suited for postmenopausal women looking for simple, once-daily symptom relief. It avoids monthly bleeding by delivering hormones evenly without a break between tablets. Its dual-action formulation makes it effective at relieving a broad range of menopausal symptoms while offering endometrial protection. It is also clinically approved for bone health support in women at risk of osteoporosis.
Important Note
Kliovance should only be used under medical supervision and is not intended for women who are still menstruating or in perimenopause. It is not suitable for use in women with a history of hormone-sensitive cancer, thromboembolic disease, or liver dysfunction. Regular reviews are essential to monitor risks and benefits, especially during long-term treatment. It is not a contraceptive and should not be taken during pregnancy or breastfeeding.
